+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Single-institution experience with gemcitabine-cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine-S-1 combination therapy: a prospective feasibility study



Single-institution experience with gemcitabine-cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine-S-1 combination therapy: a prospective feasibility study



Cancer ChemoTherapy and Pharmacology 81(5): 949-955



NCCN and Japanese clinical guidelines for the treatment of biliary tract cancer (BTC) addressed gemcitabine-cisplatin combination (GC) as first-line chemotherapy for patients with advanced BTC ineligible for surgery in 2013. However, gemcitabine-S1 combination therapy (GS) has been widely used as first-line treatment in Japan because Japanese social insurance coverage of S-1 for BTC was approved prior to that of cisplatin. To elucidate the efficacy and tolerability of GC as second-line chemotherapy for patients with unresectable BTC after failure of GS. Between September 2008 and August 2011, patients with unresectable BTC who provided informed consent and received GC comprising gemcitabine at 1000 mg/m2 and cisplatin at 20 mg/m2 given on days 1 and 8 in a 3-week cycle after failure of GS were included in the present study. Clinical data from these patients were collected prospectively. Primary endpoints were overall survival and time to progression (TTP). Secondary endpoints were response and tolerability. Twenty-seven patients were analyzed. Median survival time (MST) and TTP from the beginning of second-line treatment were 6.5 and 3.3 months, respectively, whereas MST from the commencement of first-line therapy was 12.06 months. One patient showed partial response, 16 had stable disease and 10 experienced disease progression. As a result, disease control rate was 63.0%. In total, 119 courses (median, 4; range, 1-15) were administered. Discontinuation of GC due to drug toxicities was not observed. Although some issues remain to be clarified, mainly due to the small sample size, this single-institution experience with GC as second-line treatment after failure of GS showed acceptable outcomes and good tolerability.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065516371

Download citation: RISBibTeXText

PMID: 29594362

DOI: 10.1007/s00280-018-3566-z


Related references

Treatment Outcomes of Gemcitabine and Cisplatin Combination Therapy for Unresectable and Recurrent Biliary Tract Cancer. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 45(13): 2414-2416, 2019

Erlotinib plus gemcitabine combination therapy in patients with unresectable advanced pancreatic cancer - a single-institution experience. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 40(12): 1884-1886, 2014

A retrospective study of gemcitabine and cisplatin combination therapy as second-line treatment for advanced biliary tract cancer. ChemoTherapy 59(2): 106-111, 2014

Downsizing Chemotherapy for Initially Unresectable Locally Advanced Biliary Tract Cancer Patients Treated with Gemcitabine Plus Cisplatin Combination Therapy Followed by Radical Surgery. Annals of Surgical Oncology 22(Suppl. 3): S1093-9, 2016

Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer. Journal of Hepato-Biliary-Pancreatic Sciences 22(11): 789-794, 2016

Gemcitabine in Combination with Cisplatin in Patients with Unresectable Advanced or Recurrent Biliary Tract Cancer--A Multicenter Prospective Observational Study in Fukuoka. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 42(10): 1185-1189, 2016

O1-043 * Second-Line Therapy Of S-1 For Patients With Advanced Biliary Tract Cancer After Failure To Cisplatin Plus Gemcitabine. Annals of Oncology 24(Suppl 9): ix33-ix34, 2013

Renal toxicity associated with weekly cisplatin and gemcitabine combination therapy for treatment of advanced biliary tract cancer. Oncology 87(1): 30-39, 2014

Phase I study of gemcitabine, cisplatin, and S-1 combination therapy for patients with untreated advanced biliary tract cancer. Journal of Hepato-Biliary-Pancreatic Sciences 22(9): 669-674, 2016

Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. Investigational New Drugs 29(6): 1488-1493, 2012

Gemcitabine + cisplatin (GEM+CIS) in combination with regional hyperthermia (RHT) in second-line therapy of gemcitabine-refractory metastatic pancreatic cancer. Journal of Clinical Oncology 24(18_Suppl): 14073-14073, 2016

Supportive management of cisplatin and gemcitabine combination therapy for advanced biliary tract cancer. Nihon Rinsho. Japanese Journal of Clinical Medicine 73(Suppl. 2): 592-596, 2015

Initial safety and efficacy of cisplatin and gemcitabine combination chemotherapy for unresectable biliary tract cancer. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(13): 2599-2602, 2015

A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002). Cancer ChemoTherapy and Pharmacology 75(2): 293-300, 2015

A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer. Cancer ChemoTherapy and Pharmacology 71(4): 973-979, 2013